LPIN1 and acute myeloid leukemia: To determine the impact of LPIN1 silencing on primary AML cells, three patient‐derived xenograft (PDX) AML samples including one with complex karyotype and TP53 mutation (AML‐661, AML‐372, and AML‐602; see Table S3 for genetic details) were transduced with shRNAs against LPIN1 or shLuc control.